


I hereby certify that this correspondence is being deposited with the US Post Office with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents Washington, D.C.
20231 on 11-6-2000


Timothy H. Van Dyke, Patent Attorney



RECEIVED

NOV 16 2000

TECH CENTER 1600/2900

#6Q
11-21-00
P2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. : 09/360,199
Filed : 7/23/1999
Applicants : Gauldie *et al.*
Title : Intestinal Gene Therapy
Group Art Unit : 1632
Examiner : Schnizer
Docket No. : GDI-1

To: Assistant Commissioner for Patents
Washington, D.C. 20231


AMENDMENT UNDER 37 C.F.R. § 1.111

In response to the Office Action mailed June 6, 2000, Applicants make the following amendments and remarks:

In the claims

Claim 1 (amended):

1. A method for delivery of a pharmaceutical composition to gastrointestinal or genitourinary cells in a recipient in need thereof which comprises


(a) contacting the intended site of delivery of said pharmaceutical composition with an agent adequate to cause a temporary disruption of the mucosal lining covering said gastrointestinal or genitourinary cells; and

(b) concurrently or subsequent to said contacting of step (a), contacting said gastrointestinal or genitourinary cells with said pharmaceutical composition, wherein said